Eli Lilly (LLY) Q3 2026 Earnings

Reported Oct 29, 2026, 7:03am ET · SEC source

$7.48

Beat +12.17%

EPS · est. $6.67 Adjusted

Non-GAAP EPS includes $4.57 per share of acquired IPR&D charges ($4,181 million, primarily from the AtaiBeckley and Curevo acquisitions) vs. $0.71 in Q3 2025; Q3 revenue included approximately $900 million of benefits, including $410 million of Jardiance milestones and favorable rebate/discount estimate adjustments.

$24.4B

Beat +7.88%

Revenue · est. $22.6B

6 quarters

Consecutive EPS beats

Did LLY Beat Earnings? Q3 2026 Results

Yes. Eli Lilly reported Q3 2026 earnings of $7.48 a share on Oct 29, 2026, beating the $6.67 consensus estimate by 12.2%. Revenue was $24.4B against a $22.6B estimate.

LLY Revenue by Segment

Mounjaro$10.7B+65.0%

Zepbound$5.4B+49.0%

Verzenio

Jaypirca$228.0M+59.0%

Ebglyss$202.0M+59.0%

Kisunla$193.0M+175.0%

Foundayo$184.0M

Omvoh$114.0M+76.0%

LLY Revenue by Geography

United States$15.1B+34.0%

Rest of World$9.3B+47.0%

Figures from SEC filings and company reports. Not investment advice.